2. Protein Tyrosine Kinase/RTK Anti-infection PI3K/Akt/mTOR
  3. TAM Receptor SARS-CoV Akt
  4. SLC-391

SLC-391 is an orally active AXL kinase inhibitor with an IC50 of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer.

For research use only. We do not sell to patients.

SLC-391

SLC-391 Chemical Structure

CAS No. : 1783825-18-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SLC-391 Related Antibodies

Top Publications Citing Use of Products

View All TAM Receptor Isoform Specific Products:

View All Isoforms
Axl Mer Tyro3

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SLC-391 is an orally active AXL kinase inhibitor with an IC50 of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer[1].

In Vitro

SLC-391 (0-1 μM; 0-72 h) inhibits SARS-CoV-2 infection of Vero E6 cells in a dose-dependent manner[1].
SLC-391 (0-1.5 μM; 58 h) dose-dependently blocks the binding of SARS-CoV-2 spike protein to ACE2[1].
SLC-391 (0-10 μM, 4 days) protects RPMI2650 cells from cytopathic effects induced by human influenza virus, with an EC50 of 0.14 μM, a TC50 >10 μM, and a TI greater than 71.4[1].
SLC-391 (0.003-10 μM; 4 days) reduces human influenza virus yields in RPMI2650 cells in a concentration-dependent manner in vitro, with reductions of 952.9-fold, 74.9-fold, and 34.8-fold at concentrations of 10 μM, 0.4 μM, and 0.003 μM, respectively[1].
SLC-391 inhibits Gas6-induced AXL-dependent Akt phosphorylation in human non-small cell lung cancer A549 cells with an IC50 of 0.29 μM[1].
SLC-391 inhibits the proliferation of AXL-expressing 4T1 cells (IC50 1.05 μM) and K562 cells (IC50 3.45 μM)[1].
SLC-391 (1 μM) completely inhibits the anchorage-independent proliferation of human non-small cell lung cancer A549 cells[1].
SLC-391 (0.2 μM) inhibits the invasive ability of human non-small cell lung cancer A549 cells by approximately 75%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SLC-391 Related Antibodies

Real Time qPCR[1]

Cell Line: Vero E6 cells
Concentration: 0, 0.01, 0.1, 1 μM
Incubation Time: 0, 24, 72 h
Result: Inhibited SARS-CoV-2 infection in a dose-dependent manner, as indicated by increased qPCR cycle counts.
Effectively inhibited viral infection at 0.01 μM for 24 hours.
Maintained a high degree of viral inhibition at 1 μM for up to 72 hours.

Cell Cytotoxicity Assay[1]

Cell Line: RPMI2650 cells
Concentration: 0, 0.003, 0.02, 0.08, 0.4, 2, 10 μM
Incubation Time: 4 days
Result: Exhibited cytoprotective effects against Flu A-induced cytopathic effects, with an EC50 of 0.14 μM.
Showed no significant cytotoxicity up to 10 μM, with a TC50 >10 μM, resulting in a therapeutic index above 71.4.
In Vivo

SLC-391 (50-75 mg/kg; p.o.; twice daily) achieves a 60% tumor growth inhibition rate at a dose of 50 mg/kg twice daily, and a 67% tumor growth inhibition rate at a dose of 75 mg/kg twice daily, in mouse solid tumor xenograft models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 mice[1]
Dosage: 50 mg/kg; 75 mg/kg
Administration: p.o.; twice daily
Result: Achieved 60% tumor growth inhibition (TGI).
Achieved 67% tumor growth inhibition (TGI).
Reduced levels of phosphorylated Akt in tumor xenograft samples by 41%.
Clinical Trial
Molecular Weight

365.43

Formula

C19H23N7O
CAS No.
SMILES

NC1=C(C=C(C2=CN(C3CCNCC3)N=C2)C=N1)C4=NN=C(CC5CC5)O4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SLC-391 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SLC-3911783825-18-2SLC391SLC 391TAM ReceptorSARS-CoVAktTyro3AxlMerSARS coronavirusPKBProtein kinase BGas6CHO-hACE2 cellssevere acute respiratory syndrome (SARS)influenza virusSARS-CoV-2Vero E6 cellsACE2middle east respiratory syndrome (MERS)AXL kinaseCOVID-19triple-negative breast cancerchronic myeloid leukemianon-small cell lung cancerCD-1 miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SLC-391
Cat. No.:
HY-177332
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.